by secretome | Mar 24, 2026 | News
WASHINGTON, March 24, 2026 /PRNewswire/ — Parent Project Muscular Dystrophy (PPMD), the leading U.S. non-profit driving Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, and Secretome Therapeutics (Secretome) are excited to announce...
by secretome | Dec 29, 2025 | News
PLANO, Texas–(BUSINESS WIRE)–Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that it will present at the 2026 J.P....
by secretome | Oct 28, 2025 | News
PLANO, Texas–(BUSINESS WIRE)–Secretome Therapeutics today announced the launch of a Phase 1, dose-escalating trial of STM-01, Secretome’s neonatal cardiac progenitor cell (nCPC) product, for the treatment of heart failure in young adults with dilated...
by secretome | Oct 6, 2025 | News
FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 /PRNewswire/ — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage...
by secretome | Sep 10, 2025 | News
Funding will support preclinical evaluation of STM-01 and STM-03 for Friedreich’s Ataxia. Secretome Therapeutics announced today that it has been awarded a $400,000 research grant from the Friedreich’s Ataxia Research Alliance (FARA), a leading global patient advocacy...
